Join Skye Bioscience for a virtual key opinion leader (KOL) event to discuss expectations and details of upcoming topline results from the Phase 2a CBeyond™ trial of nimacimab, a first-in-class peripheral CB1 antibody for obesity.

The event will feature distinguished obesity KOLs, Sean Wharton, MD, FRPC, PharmD (Wharton Medical Clinic), Kevin Cannon, MD (Principal Investigator, Accellacare Clinical Research), and Marcus Goncalves, MD, PhD (NYU Langone Health), and will cover expectations and details of the upcoming Phase 2a CBeyond™ topline results readout including:

• What constitutes success in Skye’s Phase 2a proof-of-concept study
• Mechanism and potential role of peripheral CB1 inhibition as a differentiated and complementary anti-obesity therapeutic pathway to other mechanisms of action
• Highlights of newly generated preclinical data

A live Q&A session will follow the formal presentations.